Armouring Car Ts may be the answer.
“armouring” element on C-CAR031 comprises a co-expressed dominant-negative TGFβ receptor that’s been truncated, so it lacks an intracellular domain necessary for downstream signalling. This feature is designed to protect the Car-T cells from TGFβ-driven immunosuppression. |
A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.
“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview. |
They are publishing early data PB.
See post 7906
Certainly won't do us any harm. |
We are in a very tight holding pattern so sifting the tea leaves to find any hopes of an exit are for passing the time of day - not taking it all too seriously alongside the technical charting stuff.... |
How big was the 'chunky buy'? Is it feasible that the 20-50k lots dumped were small enough to make the buy decently profitable? |
Well for weeks it seems some punter has been dumping 20-50k lots into the closing auction at the end of the day relentlessly.
Well today a change of something as the closing chunkier trade appears to be a buy - make of that what you will... |
We might get a shout-out.HTTps://www.linkedin.com/posts/cabalettabio_cabaletta-symposium-at-eular-2024-activity-7204895225889046529-SaDH?utm_source=share&utm_medium=member_android |
This is what accumulation looks like, designed to shake you out of your position.This chart structure was inevitable (see my earlier post), there may be a stop triggering drop before the next leg up to low 400s all imo dyor ofc. |
few buyers and sellers early on - as more arrive to trade spreads can narrow typically |
It seems now that most days at the beginning of trading there is a very large spread, up to 20p. During the day this then narrows and it ends up at the close of only about 1p. Does anyone know why ? |
I suppose what I am really saying is that it will be iteresting to watch today what technical traders do who religously follow this stuff - I am typically a LTBH so only spectate on this for background interest... |
 Does anyone follow technical charting here - well if not, please ignore. But if this is of interest we have the somewhat unusual 3 white soldier bullish pattern
hxxps://cdn.howtotradeblog.com/wp-content/uploads/2020/05/30232235/where-the-pattern-appears-2-1068x670.jpg
hxxps://www.investopedia.com/terms/t/three_white_soldiers.asp
Because three white soldiers is a bullish visual pattern, it is used as a potential entry or exit point for a trade. Traders who are short on the security look to exit and traders who are waiting to take a bullish position see the three white soldiers as an entry opportunity. When trading the three white soldiers pattern, it's important to note that the strong moves higher could create temporary overbought conditions. The relative strength index (RSI), for example, may have moved above 70.0 levels. In some cases, there is a short period of consolidation following the three white soldiers pattern, but the short- and intermediate-term bias remains bullish. The significant move higher could also reach key resistance levels where the stock could experience a period of consolidation before continuing to move higher.
Limitations of Using Three White Soldiers
Three white soldiers can also appear during periods of consolidation, which is an easy way to get trapped in a continuation of the existing trend rather than a reversal. One of the key things to watch is the volume supporting the formation of three white soldiers. Any pattern on low volume is suspect because it is the market action of the few rather than the many.
dyor/nai etc |
I thought you might Dominic... |
I second that Mr President Sir. |
DD
I don't believe he means what you believe he means. I suspect he's suggesting he's simply trading a price move irrespective of the company. Traders do that. They'll trade a chart pattern whether it's gold, oil, wheat, stocks, currencies etc. |
I have recently been studying freestyle charting of the Shaolin Temple school, and the Loch Ness monster / begging Scottie dog / giant W formation tells me that we are due big news soon.
Possibly tomorrow. |
This guy's a chart trader so uninterested in company fundamentals (ie not an investor).
with chart display |
Marketmakers trying to tempt people out of their shares? |
Short term breakout here. Itching to go |
Cytotherapy Journal (anyone subscribe secretly?)
Volume 26, Issue 6, Supplement, June 2024, Page S208
Seems a very nice summary |
Best of luck Phil and top marks for trying.
After I wrote that last post I was thinking that if they had some kind of planned schedule of updates then they would almost certainly have told us already. As they haven't, it suggests to me that it's more something which they will just roll out every time they update the corporate presentation (e.g. the JPM conference) or attach it as part of any significant RNS.
You know my logic with this already, but I'm pretty convinced that something of significance to us is on the boil.
It started with none of the insiders buying after the results - what embargoed that?
Then we have all the job ads, not least the purchasing job with a £100m spend.
We know from the AGM agenda that they plan no more big purchases with dilutions.
I've mentioned Malaria a lot, but I have a feeling that because of infrastructure and logistical needs in Africa it will be ages before demand outstrips what Serum can easily supply, so I have my doubts it is that.
If the recent RNS (new undisclosed US CAR-T partner for multiple myeloma) is J&J with Carvykti (and as Plutonian pointed out at the time, nothing else fits that description well) then pretty soon we are going to making a lot of vector either directly for J&J or for their strategic partner Legend Biotech. That would be very nice, but is it a gamechanger?
So either that or something else which is an unknown unknown. |
I’m going to write to IR and ask. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
